Osteoporosis and erectile dysfunction are rarely discussed in the same consultation. One is filed under skeletal medicine and, in most clinicians' mental model, under women's health; the other under urology or sexual medicine. Yet a growing body of population data suggests the two conditions travel together in men far more often than chance would predict, and that the overlap is not coincidental. Bone and erectile tissue depend on the same vascular supply, the same endocrine signalling, and in part the same intracellular enzymes. When one system begins to fail, it is reasonable to ask what the other is doing.
This article reviews what the evidence actually establishes about the association, what mechanisms plausibly explain it, and what it means for how men over 40 are evaluated.
The Epidemiological Signal: ED Precedes Measurable Bone Loss
The clearest data come from Taiwan's National Health Insurance Research Database, which captures essentially the entire insured population and allows long observation windows.
In a cohort study published in Medicine in 2016, Wu and colleagues followed 4,460 men aged 40 and over who were diagnosed with erectile dysfunction between 1996 and 2010, alongside 17,480 age-matched men without ED in a 1:4 ratio [1]. Over follow-up, 5.92% of the ED group developed osteoporosis compared with 3.65% of the non-ED group. Expressed as incidence, that is 9.74 versus 2.47 cases per 1,000 person-years — a 3.04-fold higher rate after adjustment for covariates. Notably, the elevation held for both psychogenic ED (3.19-fold) and organic ED (3.03-fold), and the authors reported that the association was particularly pronounced in younger men.
The same group examined a harder endpoint in PLoS One the same year: hip fracture [2]. Among 4,636 men with ED and 18,544 matched controls, 1.27% of the ED group sustained a hip fracture versus 0.75% of controls. After adjustment, the overall incidence was 3.74 times higher in the ED group (2.03 versus 0.50 per 1,000 person-years). The divergence was sharpest early — during the three-year follow-up window the hazard ratio reached 7.85 (95% CI 2.94–20.96; P < 0.0001). The authors concluded that men with ED, especially those aged 40 to 59, should undergo bone mineral density testing as early as possible.
Two caveats deserve emphasis. These are observational cohorts, so they establish association rather than causation, and insurance-claims diagnoses of both ED and osteoporosis are subject to detection bias: a man who presents for one complaint is more likely to be investigated for others. But the magnitude of the hip fracture signal — an objective, hard-to-misclassify outcome — is difficult to explain away entirely through surveillance effects.
Why Bone and Erectile Tissue Fail Together
The mechanistic case rests on a simple observation: bone is not inert mineral scaffolding. It is a densely vascularised, metabolically active tissue that remodels continuously, and that remodelling depends on perfusion.
Erectile function is, likewise, fundamentally a vascular event. It requires intact endothelium, adequate nitric oxide release, and the capacity of smooth muscle to relax in response to that signal. Endothelial dysfunction — the early, reversible stage of vascular disease — reliably shows up in the cavernosal arteries before it becomes clinically obvious in the coronary circulation, which is why ED is now widely treated as a sentinel marker of cardiovascular risk.
The same endothelial failure that limits penile blood flow appears to limit skeletal perfusion. Reduced blood flow to bone impairs the delivery of osteoblast precursors and nutrients to sites of remodelling, and chronic low-grade inflammation and oxidative stress — both features of endothelial dysfunction — independently shift the balance of bone turnover toward resorption. Under this model, ED and declining bone mineral density are two readouts of a single underlying microvascular problem, with the erectile symptom simply becoming noticeable first because it is impossible to ignore.
Shared risk factors reinforce the pattern. Type 2 diabetes, smoking, chronic kidney disease, sedentary behaviour, excess alcohol intake, and long-term corticosteroid use each independently raise the risk of both conditions. Any serious evaluation has to account for this confounding rather than assume a direct causal arrow.
Testosterone: The Shared Upstream Regulator
The most obvious common pathway is androgenic. Testosterone contributes to libido and to the normal physiology of erectile tissue, and it is also a principal regulator of male skeletal integrity — partly directly, and partly through aromatisation to oestradiol, which is a key brake on bone resorption in men.
Clinical practice statements reflect this dual role. The European Menopause and Andrology Society position statement on testosterone replacement in older men notes that late-onset hypogonadism has been associated with metabolic syndrome, reduced bone mineral density, and increased cardiovascular morbidity and mortality risk [3]. In the same literature, reduced libido and erectile dysfunction, reduced muscle mass, increased adiposity, and low bone mass are described as core features of the same hypogonadal syndrome.
This matters for interpretation. A meaningful fraction of the osteoporosis-ED overlap may simply be hypogonadism presenting through two different organ systems. It also means that in a man presenting with ED and a low-trauma fracture, or with ED before the age of 60, morning total testosterone is a reasonable part of the workup — alongside the other elements covered in our overview of erectile dysfunction evaluation and the relationship between low testosterone and erectile dysfunction.
Vitamin D, Vitamin K2, and the Calcium Paradox
Two fat-soluble vitamins sit at the intersection of bone metabolism and vascular health, and the relationship between them is more interesting than either in isolation.
Vitamin D status has been repeatedly linked to erectile function. A 2022 systematic review and meta-analysis in Urologia Internationalis pooled four studies of men with type 2 diabetes and found that serum vitamin D was significantly lower in those with concurrent erectile dysfunction than in those with diabetes alone, with a weighted mean difference of 12.5 nmol/mL (P = 0.002) [4]. The authors concluded that vitamin D may be a risk factor in this population. This is observational and restricted to a diabetic cohort, so it should not be read as evidence that supplementation treats ED — but it is consistent with the broader literature on vitamin D deficiency and erectile dysfunction and with vitamin D's established role in bone mineralisation.
Vitamin K2 addresses the other half of the problem. Vitamin K-dependent proteins, notably matrix Gla-protein, inhibit calcification in soft tissue, and their activation through carboxylation depends on vitamin K availability. In the Rotterdam Study, Geleijnse and colleagues followed 4,807 participants and found that the highest tertile of dietary menaquinone (vitamin K2) intake was associated with a relative risk of coronary heart disease mortality of 0.43 (95% CI 0.24–0.77) compared with the lowest tertile, along with reduced all-cause mortality (RR 0.74; 95% CI 0.59–0.92) and substantially less severe aortic calcification (OR 0.48; 95% CI 0.32–0.71) [5]. Phylloquinone — vitamin K1 — showed no such relationship.
The practical implication is directional rather than prescriptive. Vitamin D increases calcium absorption; vitamin K2 is involved in directing that calcium toward bone matrix rather than arterial wall. For a man whose underlying problem is simultaneous bone demineralisation and vascular calcification, the two nutrients address complementary halves of the same disorder, which is why they are increasingly formulated together rather than separately.
What PDE5 Inhibitors Do to Bone
The most unexpected thread in this literature concerns the drugs used to treat ED themselves.
In 2020, Kim and colleagues at the Mount Sinai Bone Program reported in the Proceedings of the National Academy of Sciences that tadalafil and vardenafil — two PDE5 inhibitors long used for erectile dysfunction — triggered bone gain in mice through a combination of anabolic and antiresorptive actions [6]. Both compounds enhanced osteoblastic bone formation in vivo with a distinctive gene signature, and inhibited osteoclast formation. Critically, the target enzyme PDE5A was found to be expressed in mouse and human bone, as well as in specific brain regions governing sympathetic outflow, including the locus coeruleus, raphe pallidus, and the paraventricular nucleus of the hypothalamus. The authors traced a sympathetic bone-brain circuit and concluded that the net osteoprotective effect reflects a balance between peripheral and central PDE5A blockade.
This finding must be read carefully. It is preclinical work in mice. The relative potency of the two drugs was in fact reversed in mice compared with humans, for a structural reason the authors identified — a single methionine residue at position 806 in mouse PDE5A that sterically clashes with vardenafil. No randomised controlled trial has demonstrated that PDE5 inhibitors prevent fractures in men, and nobody should take one for that purpose. What the study does establish is that the enzyme targeted by standard ED therapy is present and active in human bone, which supplies a concrete molecular link between the two conditions rather than a purely circumstantial one.
Conclusion
The evidence does not show that osteoporosis causes erectile dysfunction, or the reverse. What it shows is that the two conditions share vascular, hormonal, and enzymatic territory, and that in large population cohorts men diagnosed with ED went on to develop osteoporosis at roughly three times the expected rate and hip fracture at nearly four times the expected rate. For a 45-year-old man presenting with new erectile difficulty, the clinically useful reframing is that the symptom may be reporting on more than sexual function.
That argues for a broader workup than ED alone typically receives: cardiovascular risk assessment, morning testosterone, metabolic screening, and — particularly in men aged 40 to 59, where the fracture signal was strongest — a conversation about bone mineral density testing. It also argues for taking the unglamorous inputs seriously, since resistance training, adequate protein, smoking cessation, and sufficient vitamin D and K2 status support both systems at once. More context on related risk factors is available across our clinical library.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. Its daily formulation, EPIQ CHEWS, combines tadalafil and vardenafil with vitamin D3 and K2 — a combination that reflects the overlapping vascular and skeletal biology described above.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Wu CH, Lu YY, Chai CY, Su YF, Tsai TH, Tsai FJ, Lin CL. Increased risk of osteoporosis in patients with erectile dysfunction: A nationwide population-based cohort study. Medicine (Baltimore). 2016;95(26):e4024. doi:10.1097/MD.0000000000004024
- Wu CH, Tung YC, Lin TK, Chai CY, Su YF, Tsai TH, Tsai CY, Lu YY, Lin CL. Hip fracture in people with erectile dysfunction: A nationwide population-based cohort study. PLoS One. 2016;11(4):e0153467. doi:10.1371/journal.pone.0153467
- Kanakis GA, Pofi R, Goulis DG, Isidori AM, Armeni E, Erel CT, et al. EMAS position statement: Testosterone replacement therapy in older men. Maturitas. 2023;178:107854. doi:10.1016/j.maturitas.2023.107854
- Liu G, Wu X, Zhang Y, Zhang W, Jiang H, Dai Y, Zhang X. Serum vitamin D level and erectile dysfunction in type 2 diabetes mellitus: A systematic review and meta-analysis. Urologia Internationalis. 2022;106(10):1025-1032. doi:10.1159/000523691
- Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. Journal of Nutrition. 2004;134(11):3100-3105. doi:10.1093/jn/134.11.3100
- Kim SM, Taneja C, Perez-Pena H, Ryu V, Gumerova A, Li W, et al. Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass. Proceedings of the National Academy of Sciences USA. 2020;117(25):14386-14394. doi:10.1073/pnas.2000950117
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.